Windlas Biotech liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
6.17×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.95×1.95×2.11×2.52×2.92×
1.76×1.76×1.78×2.15×2.31×
269269224179110
306306276260233
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

WINDLAS₹923.40

Windlas Biotech Limited

· Pharma & Health
₹ CrorePeersHESTERBIOINDOCOSAIPARENTSYNCOMFPANACEABIONGLFINEHIKALJAGSNPHARMMcap ₹1,949 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Altman Z-Score (Other Equity as RE)————6.17
Current Ratio2.922.522.111.951.95
Quick Ratio2.312.151.781.761.76
Cash, Equiv & ST Investments110.2178.7223.8268.9268.9
Working Capital232.7259.9275.7305.9305.9
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.